Chen Wenli, Xu Qinlong, Ma Xiaodong, Mo Jiajia, Lin Gaofeng, He Guangwei, Chu Zhaoxing, Li Jiaming
College of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China; Hefei Industrial Pharmaceutical Institute Co., Ltd., Hefei, Anhui 230061, China.
Hefei Industrial Pharmaceutical Institute Co., Ltd., Hefei, Anhui 230061, China.
Bioorg Med Chem Lett. 2023 Jan 15;80:129101. doi: 10.1016/j.bmcl.2022.129101. Epub 2022 Dec 5.
In this study, a series of structurally novel N-(benzene sulfonyl) acetamide derivatives were designed, synthesized, and biologically evaluated as COX-2/5-LOX/TRPV1 multitarget inhibitors for anti-inflammatory and analgesic therapy. Among them, 9a and 9b displayed favorable COX-2 (9a IC = 0.011 μM, 9b IC = 0.023 μM), 5-LOX (9a IC = 0.046 μM, 9b IC = 0.31 μM) and TRPV1 (9a IC = 0.008 μM, 9b IC = 0.14 μM) inhibitory activities. The pharmacokinetic (PK) study of 9a in SD rats at the dosage of 10 mg/kg demonstrated a high oral exposure, an acceptable clearance and a favorable bioavailability (Cmax = 5807.18 ± 2657.83 ng/mL, CL = 3.24 ± 1.47 mL/min/kg, F = 96.8 %). Further in vivo efficacy studies illustrated that 9a was capable of ameliorating formalin-induced pain and inhibiting capsaicin-induced ear edema.
在本研究中,设计、合成了一系列结构新颖的N-(苯磺酰基)乙酰胺衍生物,并对其作为COX-2/5-LOX/TRPV1多靶点抑制剂用于抗炎和镇痛治疗进行了生物学评价。其中,9a和9b表现出良好的COX-2(9a IC = 0.011 μM,9b IC = 0.023 μM)、5-LOX(9a IC = 0.046 μM,9b IC = 0.31 μM)和TRPV1(9a IC = 0.008 μM,9b IC = 0.14 μM)抑制活性。9a在SD大鼠中以10 mg/kg剂量进行的药代动力学(PK)研究显示出高口服暴露量、可接受的清除率和良好的生物利用度(Cmax = 5807.18 ± 2657.83 ng/mL,CL = 3.24 ± 1.47 mL/min/kg,F = 96.8%)。进一步的体内药效学研究表明,9a能够改善福尔马林诱导的疼痛并抑制辣椒素诱导的耳部水肿。